KRAS G12C mutation in metastatic colorectal cancer: a new target

Future OncologyVol. 19, No. 24 EditorialKRASG12C mutation in metastatic colorectal cancer: a new targetRebecca Ibrahim, Khalil Saleh, Claude Chahine, Rita Khoury, Nadine Khalife & Axel LecesneRebecca IbrahimInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France, Khalil Saleh *Author for correspondence: Tel.: +33 142 114 211; E-mail Address: khalil_saleh@live.comhttps://orcid.org/0000-0002-2985-2202International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France, Claude ChahineInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France, Rita KhouryInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, France, Nadine KhalifeDepartment of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, France & Axel LecesneInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FrancePublished Online:21 Aug 2023https://doi.org/10.2217/fon-2023-0223AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: adagrasibcolorectal cancerKRASG12C mutationRASsotorasibReferences1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 14(2), 89–103 (2019).Medline, CAS, Google Scholar2. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol. Med. 13(1), 120–135 (2016).Crossref, Medline, CAS, Google Scholar3. Won DD, Lee JI, Lee IK, Oh S-T, Jung ES, Lee SH. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. BMC Cancer 17(1), 403 (2017).Crossref, Medline, Google Scholar4. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J. Biomed. Biotechnol. 2010, 150960 (2010).Crossref, Medline, Google Scholar5. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol. Res. Pract. 205(12), 858–862 (2009).Crossref, Medline, CAS, Google Scholar6. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477), 548–551 (2013).Crossref, Medline, CAS, Google Scholar7. Jones RP, Sutton PA, Evans JP et al. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br. J. Cancer 116(7), 923–929 (2017).Crossref, Medline, CAS, Google Scholar8. Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 32(9), 1101–1110 (2021).Crossref, Medline, CAS, Google Scholar9. Skoulidis F, Li BT, Dy GK et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384(25), 2371–2381 (2021).Crossref, Medline, CAS, Google Scholar10. Fakih MG, Kopetz S, Kuboki Y et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23(1), 115–124 (2022).Crossref, Medline, CAS, Google Scholar11. Weiss J, Yaeger RD, Johnson ML et al. LBA6 KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann. Oncol. 32(Suppl. 5), S1294 (2021).Crossref, Medline, Google Scholar12. Goebel L, Müller MP, Goody RS, Rauh D. KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Med. Chem. 11(7), 760–770 (2020).Crossref, Medline, CAS, Google Scholar13. Singh A, Greninger P, Rhodes D et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15(6), 489–500 (2009).Crossref, Medline, CAS, Google Scholar14. Prenen H, Fakih M, Falchook G et al. SO-39 evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: exploratory plasma biomarker analysis of CodeBreaK 100. Ann. Oncol. 33(Suppl. 4), S373 (2022).Crossref, Google Scholar15. Amodio V, Yaeger R, Arcella P et al. EGFR blockade reverts resistance to KRASG12C inhibition in colorectal cancer. Cancer Discov. 10(8), 1129–1139 (2020).Crossref, Medline, CAS, Google Scholar16. Ryan MB, Coker O, Sorokin A et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 39(12), 110993 (2022).Crossref, Medline, CAS, Google Scholar17. Kuboki Y, Yaeger R, Fakih M et al. 45MO sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort. Ann. Oncol. 33(Suppl. 9), S1445–S1446 (2022).Crossref, Google Scholar18. Yaeger R, Weiss J, Pelster MS et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. New Engl. J. Med. 388(1), 44–54 (2023).Crossref, Medline, CAS, Google Scholar19. Yaeger R, Mezzadra R, Sinopoli J et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 13(1), 41–55 (2023).Crossref, Medline, CAS, Google Scholar20. Canon J, Rex K, Saiki AY et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781), 217–223 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 19, No. 24 STAY CONNECTED Metrics Downloaded 76 times History Received 19 March 2023 Accepted 18 July 2023 Published online 21 August 2023 Published in print August 2023 Information© 2023 Future Medicine LtdKeywordsadagrasibcolorectal cancerKRASG12C mutationRASsotorasibFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download